Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 19, 2020 at 05:26 pm EDT
Share
Skinvisible, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced total revenue was USD 119,970 compared to USD 12,717 a year ago. Operating loss was USD 12,762 compared to USD 139,296 a year ago. Net loss was USD 312,793 compared to USD 583,011 a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.21 a year ago. For the half year, total revenue was USD 136,022 compared to USD 21,084 a year ago. Operating loss was USD 142,754 compared to USD 285,388 a year ago. Net loss was USD 742,877 compared to USD 926,110 a year ago. Basic loss per share from continuing operations was USD 0.17 compared to USD 0.32 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
